Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sterilization

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44357   clinical trials with a EudraCT protocol, of which   7383   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,400 result(s) found for: Sterilization. Displaying page 31 of 70.
    «« First « Previous 27  28  29  30  31  32  33  34  35  Next» Last»»
    EudraCT Number: 2021-003209-22 Sponsor Protocol Number: UNI50001-203 Start Date*: 2022-02-09
    Sponsor Name:UNION therapeutics A/S
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of Orismilast in Adults with Moderate-to-Severe Plaque-Type Psoriasis
    Medical condition: Moderate-to-severe plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-002524-12 Sponsor Protocol Number: BNZ-20-01-2022 Start Date*: 2023-04-13
    Sponsor Name:AZAD Pharma AG
    Full Title: A prospective, phase III, multicenter, randomized, investigator-blinded, two-arm, parallel groups, non-inferiority clinical trial for the comparison of efficacy and safety of a preservative-free Br...
    Medical condition: GLAUCOMA , OCCULAR HYPERTENSION
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005862-30 Sponsor Protocol Number: MHH-Pre-GvHD-001 Start Date*: 2009-02-23
    Sponsor Name:Medizinische Hochschule Hannover
    Full Title: Pre-emptive therapy of acute graft versus host disease according to specific proteomic patterns after allogeneic hematopoietic stem cell transplantation.
    Medical condition: Pre-emptive therapy of acute graft versus host disease with prednisolone according to specific proteomic patterns after allogeneic hematopoietic stem cell transplantation.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004870 10018652 Graft versus host reaction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-003205-29 Sponsor Protocol Number: CAP2022-1 Start Date*: 2023-02-23
    Sponsor Name:Aphaia Pharma US LLC
    Full Title: A Phase II, randomized, placebo – controlled crossover proof-of-concept study to evaluate efficacy and safety of distal jejunal-release dextrose beads formulation (APHD-012) in subjects with a path...
    Medical condition: Subjects with a pathological Oral Glucose Tolerance Test (OGTT)
    Disease: Version SOC Term Classification Code Term Level
    24.0 100000004861 10065542 Prediabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004301-27 Sponsor Protocol Number: NIBIT-M2 Start Date*: 2012-11-08
    Sponsor Name:FONDAZIONE NIBIT
    Full Title: A randomized, Phase III study of Fotemustine versus the Combination of Fotemustine and Ipilimumab in Patients with Metastatic Melanoma with brain metastasis
    Medical condition: Subjects (men and women) 18 years old presenting with Stage IV melanoma with presence of brain metastasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000003-20 Sponsor Protocol Number: MEMPSOLAR0001 Start Date*: 2021-06-08
    Sponsor Name:Aarhus University Hospital
    Full Title: AN INVESTIGATOR INITIATED, PHASE 4, OPEN-LABEL, SINGLE-ARM, SINGLE-CENTER STUDY INVESTIGATING THE RESIDUAL DISEASE MEMORY IN PSORIASIS SKIN DURING ENSTILAR® AND NARROW-BAND ULTRAVIOLET B THERAPY. ...
    Medical condition: Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004384-39 Sponsor Protocol Number: ABCSG-45 Start Date*: 2018-12-18
    Sponsor Name:Austrian Breast & Colorectal Cancer Study Group (ABCSG)
    Full Title: A prospective, open, randomized, phase II study of carboplatin/olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive ...
    Medical condition: Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoice© test)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001440-22 Sponsor Protocol Number: 831 Start Date*: 2019-07-28
    Sponsor Name:Skåne University Hospital
    Full Title: Phase 2, multicenter, randomized, open-label, controlled, 2-arm cross-over study to evaluate the clinical efficacy and safety of a renin inhibitor, aliskiren, compared to an angiotensin converting ...
    Medical condition: C3 glomerulopathy
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-006106-23 Sponsor Protocol Number: 2020/3210 Start Date*: 2021-07-21
    Sponsor Name:Gustave Roussy
    Full Title: Short-term Pre-OPerative Durvalumab (MEDI 4736) in early small triple negative breast cancer patients
    Medical condition: Untreated operable small triple negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003642-17 Sponsor Protocol Number: OFM_DUPI_01 Start Date*: 2018-11-23
    Sponsor Name:Medical University Graz
    Full Title: AN EXPLORATORY STUDY TO INVESTIGATE THE BIOAVAILABILITY AND PHARMACODYNAMICS OF DUPILUMAB IN DERMAL INTERSTITIAL FLUID OF ATOPIC DER-MATITIS PATIENTS
    Medical condition: Atopic Dermatitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002665-30 Sponsor Protocol Number: RENAISSANCE Start Date*: 2016-01-11
    Sponsor Name:Krankenhaus Nordwest gGmbH
    Full Title: Effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric jun...
    Medical condition: limited-metastatic adenocarcinoma of the stomach or esophagogastric junction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002645-37 Sponsor Protocol Number: KC706-C05 Start Date*: 2006-08-25
    Sponsor Name:Kémia, Inc.
    Full Title: A Phase II randomized double-blind placebo-controlled Study of KC706 in patients with rheumatoid arthritis inadequately controlled with a stable dose of methotrexate
    Medical condition: Active rheumatoid arthritis (RA), patients taking stable doses of methotrexate
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003753-13 Sponsor Protocol Number: P160909 Start Date*: 2019-03-19
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Full Title: Multicentre, randomized, prospective trial comparing the efficacy and safety of Infliximab to tocilizumab in refractory or relapsing Takayasu arteritis
    Medical condition: Patients with refractory or relapsing Takayasu Arteritis desease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004794-31 Sponsor Protocol Number: KIN-1902-2001 Start Date*: 2022-08-19
    Sponsor Name:Kinevant Sciences GmbH
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase 2 Study with Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects with Chronic Pulmonary Sarcoidosis
    Medical condition: chronic pulmonary sarcoidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037430 Pulmonary sarcoidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001306-30 Sponsor Protocol Number: PROICM2021-04REL Start Date*: 2021-09-13
    Sponsor Name:Institut Régional du Cancer de Montpellier
    Full Title: A prospective randomized phase II study to assess the schemas of retreatment with Lutathera® ([177Lu]Lu-DOTA-TATE) in patients with new progression of intestinal well-differentiated neuroendocrine ...
    Medical condition: Patients with new progression of intestinal well-differentiated neuroendocrine tumor.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001639-10 Sponsor Protocol Number: 787-201 Start Date*: 2023-06-09
    Sponsor Name:Intercept Pharmaceuticals, Inc.
    Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subje...
    Medical condition: Severe Alcohol-Associated Hepatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10001624 Alcoholic hepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004250-28 Sponsor Protocol Number: Psoriasi_Risa Start Date*: 2020-09-22
    Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS
    Full Title: EXPLORING THE EFFECTS OF IL-23 INHIBITION BY RISANKIZUMAB ON PSORIASIS AUTOIMMUNITY.
    Medical condition: Moderate to severe psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005362-18 Sponsor Protocol Number: HBIGforcure Start Date*: 2022-04-13
    Sponsor Name:Hannover Medical School
    Full Title: Hepatitis B immunoglobulins to induce HBsAg clearance in patients with chronic hepatitis B
    Medical condition: HBeAg negative patients with chronic HBV infection will be allocated into two different cohorts, cohort A and cohort B.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10022891 - Investigations 10052297 Hepatitis B e antigen negative PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004162-99 Sponsor Protocol Number: RAMTAS Start Date*: 2018-08-09
    Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest
    Full Title: RAMTAS A Phase III study of RAMucirumab in combination with TAS102 vs. TAS102 monotherapy in chemotherapy refractory metastatic colorectal cancer patients
    Medical condition: Advanced metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004611-13 Sponsor Protocol Number: G1T28-03 Start Date*: 2017-03-16
    Sponsor Name:G1 Therapeutics
    Full Title: Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
    Medical condition: Extensive-Stage Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) SI (Completed) HR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 27  28  29  30  31  32  33  34  35  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Aug 27 21:50:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA